Table 1.
MTHFR C677T and RFC-1 Genotype Distributions and Polymorphism Susceptibility Risks in Patients with Nephroblastoma and Neuroblastoma, Crude and Adjusted by Skin Color
| Controls | Nephroblastoma | Neuroblastoma | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | n (%) | n (%) | Crude OR (95% CI) | p | AdjustedaOR (95% CI) | p | n (%) | Crude OR (95% CI) | p | AdjustedaOR (95% CI) | p |
| MTHFR (C677T) | |||||||||||
| rs1801133 | |||||||||||
| CC | 137 (56.6) | 43 (53.7) | 1 (ref) | 1 (ref) | 36 (54.5) | 1 (ref) | 1 (ref) | ||||
| CT | 87 (36.0) | 30 (37.5) | 1.09 (0.64–1.88) | 0.73 | 1.09 (0.62–1.92) | 0.77 | 24 (36.4) | 1.05 (0.59–1.88) | 0.87 | 1.05 (0.57–1.92) | 0.88 |
| TT | 18 (7.4) | 7 (8.8) | 1.24 (0.48–3.16) | 0.65 | 1.92 (0.65–5.61) | 0.23 | 6 (9.1) | 1.27 (0.47–3.43) | 0.64 | 1.52 (0.48–4.79) | 0.47 |
| CT/TTb | 105 (43.4) | 37 (46.3) | 1.12 (0.68–1.86) | 0.65 | 1.18 (0.69–2.03) | 0.54 | 30 (45.5) | 1.09 (0.63–1.88) | 0.76 | 1.12 (0.63–2.00) | 0.69 |
| RFC-1 (G80A) | |||||||||||
| rs1051266 | |||||||||||
| GG | 76 (34.2) | 13 (17.0) | 1 (ref) | 1 (ref) | 11 (17.2) | 1 (ref) | 1 (ref) | ||||
| GA | 103 (46.4) | 38 (49.3) | 2.16 (1.07–4.33) | 0.03 | 2.55 (1.21–5.35) | 0.01 | 33 (51.6) | 2.21 (1.05–4.66) | 0.04 | 2.48 (1.13–5.44) | 0.02 |
| AA | 43 (19.4) | 26 (33.7) | 3.53 (1.65–7.59) | <0.01 | 4.23 (1.84–9.71) | <0.01 | 20 (31.2) | 3.21 (1.41–7.33) | <0.01 | 3.46 (1.45–8.24) | <0.01 |
| GA/AAb | 146 (65.8) | 64 (83.0) | 2.56 (1.33–4.95) | <0.01 | 3.07 (1.53–6.16) | <0.01 | 53 (82.8) | 2.51 (1.24–5.08) | 0.01 | 2.88 (1.36–6.07) | <0.01 |
a
OR adjusted by skin color.
b
CT/TT, GA/AA indicates at least one variant allele.
CI, confidence interval; MTHFR, methylenetetrahydrofolate reductase; OR, odds ratio; RFC-1, reduced folate carrier-1.